“SCIENCE AND TECHNOLOGY REVOLUTIONIZE OUR LIVES” RV GROUP LIVES THIS MOTTO WHILE SPONSORING THE CONFERENCE.

The theme was discussed in the 7th Southern Vietnam Open Blood Transfusion and Hematology conference on November 23rd and 24th at Sheraton Saigon. Which was organized by Ho Chi Minh City Blood Transfusion Hematology Hospital and Ho Chi Minh City Blood Transfusion Hematology Association and Grenoble Alpes University, France. RV Group Vietnam, the leading pharmaceutical company accompanied and sponsored the conference. RV Group Director Sudeshna Pan welcomed the renowned Doctor Rahul Bhargava, the Director of Hematology, Pediatric Hematology, Immunology and Stem Cell Transplantation at Fortis Memorial Research Institute. He shared insights on “New frontiers in the management of multiple myeloma”, the conference had a robust attendance of 1,400 delegates. The renowned doctor started his Stem Cell Transplantation journey from Medanta in 2010. He has completed more than 1500 transplants until date. Dr. Rahul Bhargava is credited with establishing 10 low-cost centers across India, specifically at Sarvodaya hospital, Batra hospital, Action Balaji hospital… In 2016, Dr. Rahul Bhargava became the first Indian doctor to perform and popularize stem cell transplantation in multiple sclerosis.

The conference was organized on a large scale with the latest scientific reports from international and Vietnamese experts in the fields of blood transfusion, hematological diseases, and 40 famous scientists in the field of Hematology and Hematopoietic Stem Cell Transplantation from all over the world, Japan, Australia, Sweden, India, Belgium, Singapore, Germany, Taiwan participated.

The conference covered the science and cure in an elaborate discussion on Multiple myeloma which was an incurable disorder. From 1992 to 2010, survival of myeloma patients improved, for example, in white men aged 60 to 69 years, median survival increased from 2.6 to 5 years, 0 years. Considering the progress rate of recent advances in anti-myeloma therapies for heterogeneous multiple myeloma, researchers hypothesized that median survival is expected to increase to 7.6 years in 2022. Melphalan and Prednisolone combination chemotherapy was the first breakthrough followed by autologous transplantation for myeloma control. After a decade in 2004, Thalidomide ushered in a new era of immunomodulators that act through multiple antiangiogenic and proteolytic mechanisms. Then, the introduction of Lenalidomide, which is 100 times more effective than Thalidomide but is safer and better tolerated, has optimized the treatment of multiple myeloma. In 2007, the triple therapy regimen began to show remarkable complete response rates and became the new standard of care. Over the next decade, many different combinations such as VCD, VVTD and VRD were tested in various clinical studies and currently VRD with the combination of three ingredients Bortezomib, Lenalidomide and Dexamethasone is the optimal regimen in the treatment of multiple myeloma according to NCCN recommendations.